Completed PHASE2 INTERVENTIONAL 1-arm NCT00041093

Docetaxel in Treating Patients With Persistent or Recurrent Cervical Cancer

A Phase II Evaluation Of Docetaxel (NSC #628503) In The Treatment Of Persistent Or Recurrent Squamous Cell Carcinoma Of The Cervix

Sponsor: Gynecologic Oncology Group

Conditions Cervical Squamous Cell Carcinoma, Not Otherwise Specified Recurrent Cervical Carcinoma

Interventions Docetaxel

Updated 8 times since 2017 Last updated: Jan 9, 2018 Started: Jun 30, 2002 Primary completion: Oct 23, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00041093, this PHASE2 trial focuses on Cervical Squamous Cell Carcinoma, Not Otherwise Specified and Recurrent Cervical Carcinoma and remains completed. Sponsored by Gynecologic Oncology Group, it has been updated 8 times since 2002, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE2
Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Feb 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Feb 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jun 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gynecologic Oncology Group
National Cancer Institute (NCI)

Data source: GOG Foundation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Philadelphia, United States